Merck’s COVID-19 pill cuts risk of death, hospitalization by 50% in study | Reuters

Merck & Co Inc’s experimental oral drug for COVID-19, molnupiravir, reduced by around 50% the chance of hospitalization or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
— Read on